Report cover image

Tuberculosis - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18678403

Description

Tuberculosis - Pipeline Insight, 2024



DelveInsight’s, “Tuberculosis – Pipeline Insight, 2024,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Tuberculosis Understanding

Tuberculosis: Overview

Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.

Typical symptoms of TB include:
  • a persistent cough that lasts more than 3 weeks and usually brings up phlegm, which may be bloody
  • weight loss
  • night sweats
  • high temperature
  • tiredness and fatigue
  • loss of appetite
  • swellings in the neck.
If not treated properly, TB disease can be fatal. With treatment, TB can almost always be cured. A course of antibiotics will usually need to be taken for 6 months. Several different antibiotics are used because some forms of TB are resistant to certain antibiotics.

Tuberculosis Emerging Drugs Chapters

This segment of the Tuberculosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tuberculosis Emerging Drugs
  • Telacebec (Q203): Qurient Co
Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.
  • VPM1002: Serum Institute of India
VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.

Further product details are provided in the report……..

Tuberculosis: Therapeutic Assessment

This segment of the report provides insights about the different Tuberculosis drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Tuberculosis

There are approx. 35+ key companies which are developing the therapies for Tuberculosis. The companies which have their Tuberculosis drug candidates in the mid to advanced stage, i.e. Phase III include, Qurient Co

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like
  • Late-stage products (Phase III )
  • Mid-Stage products (Phase II)
  • Early-stage products ( Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
● Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intravenous
  • Oral
● Molecule Type

Products have been categorized under various Molecule types such as
  • Small molecules
  • Peptide
  • Antibiotics
● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tuberculosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberculosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberculosis drugs.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The therapies under development are focused on novel approaches to treat/improve Tuberculosis.

Tuberculosis Report Insights
  • Tuberculosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Tuberculosis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Tuberculosis drugs?
  • How many Tuberculosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberculosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberculosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Tuberculosis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Serum Institute of India Pvt. Ltd.
  • AnHui Longcom Biologic Pharmacy
  • Biofabri, S.L
  • Immunitor LLC
  • Shanghai Jiatan Pharmatech
  • GlaxoSmithKline
  • Archivel Farma S.L.
  • LegoChem Biosciences
  • Quratis Inc
  • Aeras
  • Qurient Co.
  • Sequella, Inc.
  • Otsuka Pharmaceutical
  • Vaxil Biotherapeutics
  • Faron Pharmaceuticals
  • Tianjin CanSino Biotechnology
  • Global Alliance for TB Drug Development
  • Spero Therapeutics
Key Products
  • VPM1002
  • MTBVAC|
  • ESAT6-CFP10
  • V7
  • WX-081
  • GSK 692342
  • GSK3036656
  • RUTI
  • LCB01-0371
  • ID 93
  • AERAS-404
  • Telacebec
  • Sutezolid
  • OPC-167832
  • Tuberculosis vaccine
  • TBA 7371
  • TBAJ-876
  • SPR720

Table of Contents

60 Pages
Introduction
Executive Summary
Tuberculosis: Overview
● Causes
● Mechanism of Action
● Signs and Symptoms
● Diagnosis
● Disease Management
Pipeline Therapeutics
● Comparative Analysis
Therapeutic Assessment
● Assessment by Product Type
● Assessment by Stage and Product Type
● Assessment by Route of Administration
● Assessment by Stage and Route of Administration
● Assessment by Molecule Type
● Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
● Comparative Analysis
Telacebec (Q203): Qurient Co
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
● Comparative Analysis
WX-081: Shanghai Jiatan Pharmatech
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
● Comparative Analysis
OPC-167832: Otsuka Pharmaceutical
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
● Comparative Analysis
Tuberculosis Key Companies
Tuberculosis Key Products
Tuberculosis- Unmet Needs
Tuberculosis- Market Drivers and Barriers
Tuberculosis- Future Perspectives and Conclusion
Tuberculosis Analyst Views
Tuberculosis Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us